Spirovant
Spirovant Sciences is developing novel gene therapies for cystic fibrosis and other pulmonary diseases.
Based based in European Union (EU), Europe, Middle East, and Africa (EMEA), Spirovant works in biotechnology, genetics, medical, founded in 2016.
Its activity falls under biotechnology, genetics, medical; the profile below is assembled from public directory data.
The business is associated with European Union (EU), Europe, Middle East, and Africa (EMEA).
Its current recorded stage is Grant.
Its team size is recorded as c_00011_00050 employees.
Total disclosed funding stands at about $4.7M.
| Sector | Biotechnology, Genetics, Medical |
|---|---|
| Headquarters | European Union (EU), Europe, Middle East, and Africa (EMEA) |
| Founded | 2016 |
| Employees | c_00011_00050 |
| Stage | grant |
| Total funding | $4,725,000 |
Website: www.spirovant.com
Sign in to view the contact information we hold for Spirovant.
Create a free account
Create a free account